|
|
Interferon/STAT1 and neuregulin signaling pathways are exploratory biomarkers of cetuximab (Erbitux®) efficacy in KRAS wild-type squamous carcinomas: A pathway-based analysis of whole human-genome microarray data from cetuximab-adapted tumor cell-line models |
Oliveras Ferrarós, Cristina
; Vázquez MartÃn, Alejandro
; Queralt, Bernardo
; Adrados, Manuel
; Ortiz, Rosa
; Cufà González, SÃlvia
; Hernández Yagüe, Xavier
; Guardeño, Raquel
; Báez, Luciana
; Martin Castillo, Begoña
; Pérez MartÃnez, Maria Carmen
; López Bonet, Eugeni
; Llorens Duran, Rafael de
; Bernadó, Luis
; Brunet i Vidal, Joan
; Menéndez Menéndez, Javier Abel
|
|
|
Interferon/STAT1 and neuregulin signaling pathways are exploratory biomarkers of cetuximab (Erbitux®) efficacy in KRAS wild-type squamous carcinomas: A pathway-based analysis of whole human-genome microarray data from cetuximab-adapted tumor cell-line models |
Oliveras Ferrarós, Cristina
; Vázquez MartÃn, Alejandro
; Queralt, Bernardo
; Adrados, Manuel
; Ortiz, Rosa
; Cufà González, SÃlvia
; Hernández Yagüe, Xavier
; Guardeño, Raquel
; Báez, Luciana
; Martin Castillo, Begoña
; Pérez MartÃnez, Maria Carmen
; López Bonet, Eugeni
; Llorens Duran, Rafael de
; Bernadó, Luis
; Brunet i Vidal, Joan
; Menéndez Menéndez, Javier Abel
|
|
5 juny 2018 |
Interferon/STAT1 and neuregulin signaling pathways are exploratory biomarkers of cetuximab (Erbitux®) efficacy in KRAS wild-type squamous carcinomas: A pathway-based analysis of whole human-genome microarray data from cetuximab-adapted tumor cell-line models |
Oliveras Ferrarós, Cristina
; Vázquez MartÃn, Alejandro
; Queralt, Bernardo
; Adrados, Manuel
; Ortiz, Rosa
; Cufà González, SÃlvia
; Hernández Yagüe, Xavier
; Guardeño, Raquel
; Báez, Luciana
; Martin Castillo, Begoña
; Pérez MartÃnez, Maria Carmen
; López Bonet, Eugeni
; Llorens Duran, Rafael de
; Bernadó, Luis
; Brunet i Vidal, Joan
; Menéndez Menéndez, Javier Abel
|
|
2011 |
Interferon/STAT1 and neuregulin signaling pathways are exploratory biomarkers of cetuximab (Erbitux®) efficacy in KRAS wild-type squamous carcinomas: A pathway-based analysis of whole human-genome microarray data from cetuximab-adapted tumor cell-line models |
Oliveras Ferrarós, Cristina
; Vázquez MartÃn, Alejandro
; Queralt, Bernardo
; Adrados, Manuel
; Ortiz Duran, Maria Rosa
; Cufà González, SÃlvia
; Hernández Yagüe, Xavier
; Guardeño, Raquel
; Báez, Luciana
; Martin Castillo, Begoña
; Pérez MartÃnez, Maria Carmen
; López Bonet, Eugeni
; Llorens Duran, Rafael de
; Bernadó, Luis
; Brunet i Vidal, Joan
; Menéndez Menéndez, Javier Abel
|
|
abril 2012 |
Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts |
Cufà González, SÃlvia
; Corominas Faja, Bruna
; Vázquez MartÃn, Alejandro
; Oliveras Ferrarós, Cristina
; Dorca Ribugent, Joan
; Bosch Barrera, Joaquim
; Martin Castillo, Begoña
; Menéndez Menéndez, Javier Abel
|
|
|
Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts |
Cufà González, SÃlvia
; Corominas Faja, Bruna
; Vázquez MartÃn, Alejandro
; Oliveras Ferrarós, Cristina
; Dorca Ribugent, Joan
; Bosch Barrera, Joaquim
; Martin Castillo, Begoña
; Menéndez Menéndez, Javier Abel
|
|
|
Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts |
Cufà González, SÃlvia
; Corominas Faja, Bruna
; Vázquez MartÃn, Alejandro
; Oliveras Ferrarós, Cristina
; Dorca Ribugent, Joan
; Bosch Barrera, Joaquim
; Martin Castillo, Begoña
; Menéndez Menéndez, Javier Abel
|
|
5 juny 2018 |
Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts |
Cufà González, SÃlvia
; Corominas Faja, Bruna
; Vázquez MartÃn, Alejandro
; Oliveras Ferrarós, Cristina
; Dorca Ribugent, Joan
; Bosch Barrera, Joaquim
; Martin Castillo, Begoña
; Menéndez Menéndez, Javier Abel
|
|
21 juny 2013 |
Nous mecanismes de resistència primà ria al trastuzumab (Herceptin): bases moleculars per a la determinació d’un nou subtipus de cà ncer de mama (Basal/ErbB2+) |
Oliveras Ferrarós, Cristina
|
|
21 juny 2013 |
Nous mecanismes de resistència primà ria al trastuzumab (Herceptin): bases moleculars per a la determinació d’un nou subtipus de cà ncer de mama (Basal/ErbB2+) |
Oliveras Ferrarós, Cristina
|
|
|
Nous mecanismes de resistència primà ria al trastuzumab (Herceptin): bases moleculars per a la determinació d’un nou subtipus de cà ncer de mama (Basal/ErbB2+) |
Oliveras Ferrarós, Cristina
|
|
2008 |
Sequence-dependent synergism and antagonism between paclitaxel and gemcitabine in breast cancer cells: the importance of scheduling |
Oliveras Ferrarós, Cristina
; Vázquez MartÃn, Alejandro
; Colomer, Ramon
; Llorens Duran, Rafael de
; Brunet i Vidal, Joan
; Menéndez Menéndez, Javier Abel
|
|
|
Sequence-dependent synergism and antagonism between paclitaxel and gemcitabine in breast cancer cells: the importance of scheduling |
Oliveras Ferrarós, Cristina
; Vázquez MartÃn, Alejandro
; Colomer, Ramon
; Llorens Duran, Rafael de
; Brunet i Vidal, Joan
; Menéndez Menéndez, Javier Abel
|
|
|
Sequence-dependent synergism and antagonism between paclitaxel and gemcitabine in breast cancer cells: the importance of scheduling |
Oliveras Ferrarós, Cristina
; Vázquez MartÃn, Alejandro
; Colomer, Ramon
; Llorens Duran, Rafael de
; Brunet i Vidal, Joan
; Menéndez Menéndez, Javier Abel
|
|
5 juny 2018 |
Sequence-dependent synergism and antagonism between paclitaxel and gemcitabine in breast cancer cells: the importance of scheduling |
Oliveras Ferrarós, Cristina
; Vázquez MartÃn, Alejandro
; Colomer, Ramon
; Llorens Duran, Rafael de
; Brunet i Vidal, Joan
; Menéndez Menéndez, Javier Abel
|
|
2012 |
Transcriptional upregulation of HER2 expression in the absence of HER2 gene amplification results in cetuximab resistance that is reversed by trastuzumab treatment |
Oliveras Ferrarós, Cristina
; Massaguer i Vall-llovera, Anna
; Vázquez MartÃn, Alejandro
; Carrion Salip, Dolors
; Queralt, Bernardo
; Cufà González, SÃlvia
; Martin Castillo, Begoña
; Bosch Barrera, Joaquim
; Brunet i Vidal, Joan
; Llorens Duran, Rafael de
; Menéndez Menéndez, Javier Abel
|
|
|
Transcriptional upregulation of HER2 expression in the absence of HER2 gene amplification results in cetuximab resistance that is reversed by trastuzumab treatment |
Oliveras Ferrarós, Cristina
; Massaguer i Vall-llovera, Anna
; Vázquez MartÃn, Alejandro
; Carrion Salip, Dolors
; Queralt, Bernardo
; Cufà González, SÃlvia
; Martin Castillo, Begoña
; Bosch Barrera, Joaquim
; Brunet i Vidal, Joan
; Llorens Duran, Rafael de
; Menéndez Menéndez, Javier Abel
|
|
|
Transcriptional upregulation of HER2 expression in the absence of HER2 gene amplification results in cetuximab resistance that is reversed by trastuzumab treatment |
Oliveras Ferrarós, Cristina
; Massaguer i Vall-llovera, Anna
; Vázquez MartÃn, Alejandro
; Carrion Salip, Dolors
; Queralt, Bernardo
; Cufà González, SÃlvia
; Martin Castillo, Begoña
; Bosch Barrera, Joaquim
; Brunet i Vidal, Joan
; Llorens Duran, Rafael de
; Menéndez Menéndez, Javier Abel
|
|
5 juny 2018 |
Transcriptional upregulation of HER2 expression in the absence of HER2 gene amplification results in cetuximab resistance that is reversed by trastuzumab treatment |
Oliveras Ferrarós, Cristina
; Massaguer i Vall-llovera, Anna
; Vázquez MartÃn, Alejandro
; Carrion Salip, Dolors
; Queralt, Bernardo
; Cufà González, SÃlvia
; Martin Castillo, Begoña
; Bosch Barrera, Joaquim
; Brunet i Vidal, Joan
; Llorens Duran, Rafael de
; Menéndez Menéndez, Javier Abel
|